title: Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
abstract: Sepsis-induced systemic inflammation results in coagulation abnormalities that may be different in gram-positive and gram-negative infections. We used ciprofloxacin to induce a predominantly gram-positive Enterococcus faecalis polymicrobial sepsis in rats. Ciprofloxacin-untreated rats exhibited a predominantly gram-negative polymicrobial sepsis. Rats were subjected to 30% body surface area burn (B), cecal ligation puncture (CLP) with a 22-gauge needle, and B + CLP. Ciprofloxacin-treated B + CLP rats showed a significant decrease in plasma thrombin activatable fibrinolysis inhibitor (TAFI) levels compared with sham rats. However, plasma tissue factor pathway inhibitor (TFPI) levels decreased significantly in B, CLP, and B + CLP groups compared with sham rats. The ciprofloxacin-untreated group showed a significant decrease in plasma TAFI levels in CLP and B + CLP and plasma TFPI levels decreased in all 3 groups compared with sham rats. Histological changes in the liver and kidney included vascular congestion and parenchyma bleed following B + CLP in ciprofloxacin-untreated rats. These results suggest that plasma TAFI and TFPI levels differ depending on the type of bacteria involved in the septic process.
authors.affiliation: Department of Pediatrics, Division of Pediatric Critical Care Medicine, Children's Hospital of New York, Columbia University College of Physicians and Surgeons, New York, NY, USA. tr2148@columbia.edu
authors.forename: Thyyar M
authors.initials: TM
authors.lastname: Ravindranath
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Goto
authors.forename: Omer
authors.initials: O
authors.lastname: Iqbal
authors.forename: Michelle
authors.initials: M
authors.lastname: Florian-Kujawski
authors.forename: Debra
authors.initials: D
authors.lastname: Hoppensteadt
authors.forename: Rashid
authors.initials: R
authors.lastname: Hammadeh
authors.forename: Mohammad M
authors.initials: MM
authors.lastname: Sayeed
authors.forename: J
authors.initials: J
authors.lastname: Fareed
mesh_terms: D000818:Animals; D025901:Carboxypeptidase B2 / Q000097:blood*; D002939:Ciprofloxacin / Q000008:administration & dosage; D013293:Enterococcus faecalis; D016905:Gram-Negative Bacterial Infections / Q000097:blood; D016908:Gram-Positive Bacterial Infections / Q000097:blood; D007668:Kidney / Q000473:pathology; D008074:Lipoproteins / Q000097:blood*; D008099:Liver / Q000473:pathology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000097:blood* / Q000382:microbiology / Q000473:pathology
chemical_list: D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D002939:Ciprofloxacin; D025901:Carboxypeptidase B2